Design of Bioactive Peptides from Naturally Occurring \( \mu \)-Conotoxin Structures*§

Marijke Stevens†, Steve Peigneur‡, Natalia Dyubankova§, Eveline Lescrinier§, Piet Herdewijn§, and Jan Tytgat‡,‡

From the †Laboratory of Toxicology, Katholieke Universiteit (KU) Leuven, Campus Gasthuisberg O and N2, Herestraat 49 Box 922, 3000 Leuven, Belgium and §Laboratory of Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium

To date, cone snail toxins (“conotoxins”) are of great interest in the pursuit of novel subtype-selective modulators of voltage-gated sodium channels (Na\(_v\)). Na\(_v\)s participate in a wide range of electrophysiological processes. Consequently, their malfunction has been associated with numerous diseases. The development of subtype-selective modulators of Na\(_v\)s remains highly important in the treatment of such disorders. In current research, a series of novel, synthetic, and bioactive compounds were designed based on two naturally occurring \( \mu \)-conotoxins that target Na\(_v\)s. The initial designed peptide contains solely 13 amino acids and was therefore named “Mini peptide.” It was derived from the \( \mu \)-conotoxins KIIIA and BulIIC. Based on this Mini peptide, 10 analogues were subsequently developed, comprising 12–16 amino acids with two disulfide bridges. Following appropriate folding and mass verification, blocking effects on Na\(_v\)s were investigated. The most promising compound established an IC\(_{50}\) of 34.1 \( \pm \) 0.01 nM (R2-Midi on Na\(_v\),1.2). An NMR structure of one of our most promising compounds was determined. Surprisingly, this structure does not reveal an \( \alpha \)-helix. We prove that it is possible to design small peptides based on known pharmacophores of \( \mu \)-conotoxins without losing their potency and selectivity. These data can provide crucial material for further development of conotoxin-based therapeutics.

Voltage-gated sodium channels (Na\(_v\))§ are important transmembrane proteins with respect to generating as well as propagating action potentials in excitable cells (e.g. neuronal cells and muscular cells). Defective Na\(_v\)s cause several diseases or channelopathies like epileptic disorders (1), neuromuscular diseases (2), and cardiomyopathies (3). Blocking the aberrant Na\(_v\) current can be effective in treating these disorders. In the past, nonspecific Na\(_v\) blockers like antiepileptic drugs, anticonvulsants, or antiarrhythmics have been widely utilized as therapeutics (4). However, their use remains limited due to unwanted side effects. More selective Na\(_v\) blockers are needed.

One group of peptides recently acquiring interest in this respect is conotoxins. Conotoxins are biologically active compounds isolated from the venom of cone snails (genus Conus). Four families of conotoxins target Na\(_v\)s. These are categorized according to either their functional agonistic or antagonistic effects. \( \delta \)-Conotoxins (5) and \( \iota \)-conotoxins (6) produce agonistic effects, whereas \( \mu \)-O-conotoxins (7) and \( \mu \)-\(-\)-conotoxins (8) bring about antagonistic effects. Several excellent reviews exist on their discovery, description, and therapeutic potential (9–11). The group of toxins that is of importance in the current study is the \( \mu \)-conotoxin family.

\( \mu \)-Conotoxins display a typical folding pattern called framework III. In this conformation, three conserved disulfide bridges are formed between Cys\(_1^{-}\)-Cys\(_4^{-}\), Cys\(_2^{-}\)-Cys\(_5^{-}\), and Cys\(_3^{-}\)-Cys\(_6^{-}\) (Cys residues are numbered according to their order in the total sequence) (9). They affect Na\(_v\)s by plugging into the pore analogously to the guanidinium toxins tetrodotoxin and saxitoxin. However, they do not target precisely the same binding area (12). Other contact points on the outer channel vestibule are possibly also essential with respect to their binding (12–17).

It is their high potency as well as small size (16–26 AAs) and selectivity that renders \( \mu \)-conotoxins very interesting (18). The latter characteristic in particular is a valuable quality for the development of potential therapeutics. In our experiments, we attempted to benefit from this feature. Our strategy was to miniaturize \( \mu \)-conotoxins as much as possible as well as to improve their potency and selectivity. In addition, the peptides needed to be druggable compounds, e.g. compounds that could be synthesized economically. Removal of one disulfide bridge for instance offers a large economic advantage. Moreover, it can provide extra stability because reactive thiol groups of disulfide bridges can catalyze degradation processes (19).
Our starting point was a small and stable peptide of 13 AAs derived from two naturally occurring $\mu$-conotoxins, KIIIA from Conus kinosithai (20), and BulIIC from Conus bullatus (21). A series of 10 analogues were subsequently designed. Although they only comprise 13–16 amino acids, all peptides retained their blocking properties. Our most promising compound exhibits an IC$_{50}$ value of 34.1 nM on Na$_{\alpha}$1.2. In addition to being a very potent blocker, it displays an interesting selectivity for Na$_{\alpha}$1.2 over Na$_{\alpha}$1.4 and Na$_{\alpha}$1.6. An NMR structure of one of our most promising compounds, named Midi, was determined. Surprisingly, this structure does not reveal an $\alpha$-helix. This unique feature has never been seen in any of the known $\mu$-conotoxins.

**EXPERIMENTAL PROCEDURES**

**Chemical Synthesis of Synthetic Peptides and Analysis**—The following peptides were synthesized by Peptide 2.0 (Chantilly, VA): Mini, Mini-R5A, Mini-R5E, Midi, Extra-Mini, EAD-Midi, EAK-Midi, AA-Midi, and a Midi peptide with the following sequence: Pro-Val-Leu-Met-Glu-Ava-Asp-Met. This sequence was chosen based on its high homology to a few of the known $\mu$-conotoxins. The synthesis was performed on an automated peptide synthesizer (Advanced Bioscience Instruments, Sunnyvale, CA) using standard Fmoc solid-phase peptide synthesis methodology. The final peptides were purified by reverse-phase HPLC on an analytical Vydac C18 column as described in the previous section. Masses of the folded peptides were validated by electrospray ionization-quadrupole ion trap-mass spectrometer (XP electrospray ionization-quadrupole ion trap-mass spectrometer, Micromass, Manchester, UK) with an initial concentration of 0% (v/v) trifluoroacetic acid (TFA) in acetonitrile) and solvent B (0.085% TFA (v/v) in water) with an initial concentration of 0% TFA (v/v) in water) with a linear gradient of 0–40% acetonitrile (v/v) trifluoroacetic acid (TFA) in acetonitrile) and solvent B (0.085% TFA (v/v) in water) with an initial concentration of 0% TFA (v/v) in water). The gradient was set by means of a mixture of solvent A (0.085% TFA (v/v) trifluoroacetic acid (TFA) in acetonitrile) and solvent B (0.1% TFA (v/v) in water) with an initial concentration of 0% TFA (v/v) in water). Molecular masses were validated on an LCQ Deca XP electrospray ionization-quadrupole ion trap-mass spectrometer (Thermo Finnigan) in a positive ionization mode.

**Folding of the Peptides**—The Mini peptide was folded using two strategies. The first strategy was executed in accordance with previous studies established by our laboratory (22) and other groups (e.g. Ref. 23). A glutathione folding mixture was prepared that contained 1 mM reduced glutathione, 1 mM oxidized glutathione, 1 mM EDTA, and 100 mM Tris-HCl (pH 7.5). This reduced Mini peptide was dissolved in 0.01% (v/v) TFA before being added to the folding mixture with a final peptide concentration of 112 $\mu$M. At different time points (e.g. 30 s, 30 min, 24 h, and 1 week) subsequent to initiation of the folding reaction, aliquots were withdrawn and quenched by acidification with 8% formic acid. In the second folding strategy, peptides were dissolved in the physiological buffer solution ND-96 (see “Heterologous Expression”). Folding mixtures were retained at room temperature for at least 2–3 days. At different time points following dissolution, aliquots were withdrawn. Aliquots were analyzed with reversed-phase HPLC by means of an analytical Vydac C$_{18}$ column as described in the previous section. Masses of the folded peptides were validated by electrospray ionization MS.

**Heterologous Expression**—Complementary DNA encoding the Na$_{\alpha}$ channel was subcloned into the corresponding vector: rNa$_{\alpha}$1.2/pLCT1 (NotI), rNa$_{\alpha}$1.3/pNa3T (NotI), rNa$_{\alpha}$1.4/pUI-2 (NotI), hNa$_{\alpha}$1.5/pcDNA3.1 (XbaI), mNa$_{\alpha}$1.6/pLCT1 (NotI), rNa$_{\alpha}$1.7/pBSTa.rPN1 (SacII), rNa$_{\alpha}$1.8/pSP64T (XbaI), h$\beta$1/pGEM-HE (NheI), or r$\beta$1/pSP64T (EcoRI). Following linearization with the respective restriction enzymes (indicated in parentheses), capped cRNA was generated by in vitro transcription using the T7 (for rNa$_{\alpha}$1.2, rNa$_{\alpha}$1.3, rNa$_{\alpha}$1.4, mNa$_{\alpha}$1.6, mNa$_{\alpha}$1.7, and h$\beta$1) or the Sp6 (for hNa$_{\alpha}$1.5, rNa$_{\alpha}$1.8, and r$\beta$1) mMESSAGE mMACHINE transcription kit (Ambion, Austin, TX).

Stage V-VI oocytes were harvested by partial ovariectomy from anesthetized Xenopus laevis frogs as described previously (22). Oocytes were incubated in ND-96 solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl$_2$, 2 mM MgCl$_2$, and 5 mM HEPES (pH 7.4)) supplemented with 50 mg/liter gentamicin sulfate and 0.5 mM theophylline. Selected oocytes were injected with cRNA at 1–3 ng/ml. Injection was conducted utilizing a microinjection needle (Drummond Scientific, Broomhall, PA). Oocytes were stored for 1–5 days at 16°C until sufficient expression of Na$_{\alpha}$s was achieved.

**Electrophysiology**—Whole-cell currents from oocytes were recorded at room temperature (18–22°C) by the two-electrode voltage clamp technique using a GeneClamp 500 amplifier ( Molecular Devices, Sunnyvale, CA) controlled by a pClamp data acquisition system (Molecular Devices). Oocytes were placed in a bath containing ND-96 solution. Voltage and current electrodes were filled with 3 M KCl, and the resistances of both electrodes were maintained as low as possible (between 0.5 and 1.5 megaohms). The elicited currents were sampled at 20 kHz and filtered at 2 kHz using a four-pole, low pass Bessel filter. To eliminate the effect of the voltage drop across the bath grounding electrode, the bath potential was actively controlled by a two-electrode bath clamp. Leak subtraction was performed using a $-P/4$ protocol.

Whole-cell current traces were evoked every 5 s by a 100-ms depolarization to the voltage corresponding to the maximal activation of the Na$_{\alpha}$ subtype in control conditions, starting from a holding potential of $-90$ mV. Concentration-response curves were constructed by adding different toxin concentrations directly to the bath solution. The percentage of Na$_{\alpha}$ blockade was plotted against the logarithm of the applied concentrations and fitted with the Hill equation.

$$F(V) = 100 \left(1 - \frac{[\text{toxin}]}{IC_{50}} \right)^{-y}$$

where $y$ is the percentage of block, $IC_{50}$ is the toxin concentration at half-maximal efficacy, [toxin] is the toxin concentration, and $h$ is the Hill coefficient.

To investigate the effects on the voltage dependence of activation, current traces were induced by 100-ms depolarizations from a holding potential of $-90$ to 65 mV with 5-mV increments. The Na$^+$ conductance was calculated from the currents using Ohm’s law, $g_{Na} = I_{Na}/(V - V_{rev})$ where $I_{Na}$ is the Na$^+$ current peak amplitude at a given test potential and $V_{rev}$ is the reversal potential. The values of $g_{Na}$ were normalized and plotted as a function of voltage and fitted using the Boltzmann equation:

$$g_{Na}/g_{max} = (1 + \exp(V_g - V/k))^{-1}$$

where $g_{max}$ is the maximal $g_{Na}$, $V_g$ is the voltage corresponding to half-maximal conductance, and $k$ is the slope factor.

To investigate the effects on the steady-state inactivation process, oocytes were depolarized using a standard two-step protocol. From a holding potential of $-90$ mV, 100-ms pre-
Miniaturized μ-Conotoxins as Selective Na⁺ Blockers

pulses were generated, ranging from −90 to 65 mV with 5-mV increments, immediately followed by a 100-ms test pulse to −10 mV. The current amplitudes from the test pulse were normalized to the maximal Na⁺ current amplitude I_max and plotted as a function of the applied prepulse potential using the Boltzmann equation, I_Na/I_max = (1 + exp(V − V_h)/k)−1 where I_max is the maximal I_Na, V_h is the voltage corresponding to half-maximal activation, V is the test voltage, and k is the slope.

Statistical analysis of the experiments was performed using a one-way analysis of variance Bonferroni test (p < 0.05). All data are presented as means ± S.E. in general of at least three independent experiments (n ≥ 3).

NMR Spectroscopy—NMR spectra were recorded with a 2 mm solution of folded Midi (200 μl) in 100% D₂O and in 80% H₂O and 20% D₂O mixtures at 5 °C at 600 MHz on a Bruker Avance II 600 spectrometer equipped with a 5-mm TCI HCN Z gradient cryoprobe. Spectra were processed using Topspin (version 2.1; Bruker Biospin) and analyzed using CARA (version 1.8.4) (24, 25).

In the one-dimensional and two-dimensional spectra in 80% H₂O, the water signal was suppressed using excitation sculpting with gradients (26). The two-dimensional NOESY in H₂O was acquired using a 3-9-19 pulse sequence with gradients for water suppression allowing for presaturation during relaxation delay in cases of radiation damping (28–30).

Natural abundance ¹H,¹³C heteronuclear single quantum correlation in D₂O was recorded with sensitivity enhancement and gradient coherence selection optimized for selection of CH groups (J_CH = 145 Hz) using 64 scans and 256/1024 complex data points and 30,200/6010 Hz spectral widths in t₁ and t₂, respectively. The two-dimensional heteronuclear single quantum correlation-total correlation spectroscopy spectrum consisted of a heteronuclear single quantum correlation building block followed by a clean MLEV-17 total correlation spectroscopy transfer step of 60-ms mixing time just prior to the rephasing gradient with exactly the same spectral widths and number of points as heteronuclear single quantum correlation. The data were apodized with a shifted sine-bell square function in both dimensions of two-dimensional spectra.

Structural Constraints—Distance restraints were derived from NOESY spectra recorded with 150-ms mixing times. Estimated interproton distances were derived using the isolated spin pair approximation, r_ij = r_ref (a_ref/a_ij), where r_ij is the estimated interproton distance, r_ref is the fixed internal reference distance, and a_ref and a_ij are the NOE cross-peak intensities of the reference and estimated cross-peaks, respectively. NOE interaction within geminal methylene pairs was used to determine fixed internal reference distances of 1.8 Å. An experimental error (±20%) was used on the calculated interproton distances. ³J_HNH, coupling constants were measured from double quantum-filtered COSY spectra in H₂O and then converted to dihedral restraints as follows: ³J_HNH > 8 Hz, φ = −120 ± 30; ³J_HNH < 6 Hz, φ = −60 ± 30.

Structure Calculations—All structure calculations were performed by means of X-PLOR-NIH V3.851 (31). A set of 100 structures was generated by torsion angle molecular dynamics, starting from an extended strand and using NMR-derived restraints. After the torsion angle molecular dynamics round (32), the majority of structures had converged to very similar structures with similar total energies and no violations of the NOE and dihedral restraints. Twenty lowest energy structures were used for further refinement during the “gentle molecular dynamics” round in explicit water (33). A box of water was constructed and optimized around selected structures obtained from torsion angle dynamics. The final refinement commenced with a 20-ps constant temperature molecular dynamics simulation at 300 K (20,000 steps of 0.001 ps) and was followed by a 200-step conjugate gradient energy minimization of the average structure of the last 10 ps of the 20-ps simulation. Visual representations of the molecule were obtained with PyMOL Molecular Graphics System (version 1.3; Schrödinger, LLC).

RESULTS

Design Strategy

Mini Peptide—We attempted to design a chimeric, as much as possible minimized peptide benefiting from the particular characteristics of two μ-conotoxins, BuIIIC and KIIIA.

BuIIIC has recently been discovered in the venom of C. bulatus alongside BuIIIA and BuIIIB (21). Strikingly, they differ greatly from previously isolated μ-conotoxins because they only contain three residues in the second intercysteine loop as opposed to four (Table 1A). BuIIIC demonstrates a strong block on Na⁺, 1.4 (96% at 1 μM) (21). We retained the structural characteristics as well as its potent block.

An additional μ-conotoxin gaining our interest was KIIIA because it is the smallest μ-conotoxin identified thus far, containing 16 AAs (20). Its short first intercysteine loop contains but one Asn residue, whereas other μ-conotoxins possess at least three or even eight residues in this loop (Table 1A).

For construction of the chimeric Mini peptide, residues of the three intercysteine loops were taken into consideration as “building blocks.” The first loop is based on KIIIA and contains an Asn residue. For the second loop, we considered the sequences of BuIIIA, BuIIIB, and BuIIIC. BuIIIA and BuIIIB incorporate Gly-Arg-Trp, whereas BuIIIC encompasses the sequence Ser-Arg-Trp. A considerably larger number of μ-conotoxins bear at least one Ser residue in the second loop (Table 1A, 12 of 18). This proves to be a more favorable residue from an evolutionary viewpoint rather than Gly (Table 1A, six of 18). Hence the sequence of BuIIIC was selected to construct the second loop. Concerning the third loop, BuIIIC and KIIIA contain identical residues. In addition, comparable sequences are found in other μ-conotoxins (e.g. SIIIA, SmIIIA, and CIIIA; Table 1A). Therefore, these BuIIIC/KIIIA residues were incorporated in the chimeric peptide.

We integrated recent results by Han et al. (34) into our design strategy. They illustrated that the first disulfide bridge between
Cys$^1$ and Cys$^9$ in KIIIA is removable, almost without affecting the original activity of the peptide on Nav1.2 and Nav1.4 (34). Ultimately, the first disulfide bridge was excluded in our chimeric peptide. The resulting peptide was named “Mini peptide” by reason of its sequence of only 13 AAs (Table 1B). This renders the Mini peptide even shorter than the smallest µ-conotoxin known to date.

### TABLE 1
Sequences of naturally occurring µ-conotoxins and synthetically designed peptides

Shown are the sequences of the 19 known, naturally occurring µ-conotoxins (A), the two naturally occurring peptides KIIIA and BuIIIc from which the Mini peptide was derived and the artificially designed Mini peptide (B), and the three series of synthetic derivatives (C). Dashes are put in the sequences to make all sequences and inte cysteine loops of comparable length. “AAs” represents the total number of residues. The first sequence of all series is the sequence of the peptide from which the series is derived (e.g. the Mini peptide or Midi peptide). Residue numbers are indicated below the corresponding sequences. Black lines above the sequences, disulfide bridges; asterisks, deletions of Cys residues; red amino acids, changes as compared with the sequence of the Mini peptide (Series 1) or with the Midi peptide (Series 2 and 3); number sign (#), C-terminal amidation; Z, pyroglutamate; O, hydroxyproline. AAs in gray lie in the first intercysteine loop, AAs in turquoise lie in or are derived from the second intercysteine loop, and AAs in green lie in or are derived from the third intercysteine loop.

#### A. µ-Conotoxin

| Sequence | AAs | Cone snail | Ref. |
|----------|-----|------------|------|
| KIIIA    | ----C-C-S-SSW-CRDHS-CC | 16 | Conus kinoshitai | (20) |
| SIIIIB   | ZN----C-C-G-GCC-S-SW-CRDHAR-CC | 20 | Conus striatus | (20) |
| CPIIA    | ZRL--C-C--G--FOKSC--C-SQ-COH--R-CC | 22 | Conus purpurascens | (49) |
| GIIIA    | -RD--C-T--O--OKK-C-DR-C-QK--O--C-R-CC | 22 | Conus geographus | (50) |
| GIIIB    | -RD--C-T--O--OKK-C-DR-C-K--O--C-R-CC | 22 | Conus geographus | (50) |
| GIIIC    | -RD--C-T--O--OKK-C-DR-C-K--O--C-R-CC | 22 | Conus geographus | (50) |
| TIIIA    | -RHGC--C-G-K-G--S-SR-C-E-C-O--Q-R-CC | 22 | Conus tulipa | (51) |
| SnIIIIB  | ZR--C--C-N--G--R--G--C-S-S--R-CRDHS-CC | 22 | Conus stercusmuscarum | (52) |
| CIIIA    | GR--C-E--G--PGN--C-S-S--R--C-DHAR-CC | 22 | Conus catus | (53) |
| MIIIA    | ZG--C--C--N--V--P--N--G--S--G--R--C--D--HAR--Q--CC | 22 | Conus magus | (53) |
| CnIIIIB  | GR--C--C--D--N--V--P--N--A--C--S--G--R--C--D--HAR--Q--CC | 22 | Conus consors | (53) |
| CnIIIC   | ZG--C--C--G--P--K--G--C--S--G--R--C--D--HAR--R--CC | 22 | Conus consors | (53) |
| SrIIIIB  | -R--C-T--G--K--G--C--S--G--R--C--D--HAR--R--CC | 22 | Conus striolatus | (55) |
| BuIIIIB  | -TDR--C--C--G--K--R--G--C--S--G--R--C--D--HAR--R--CC | 22 | Conus bullatus | (21) |
| SrIIIB   | ZK--C--C--G--K--G--C--S--G--R--C--D--HAR--K--CC | 23 | Conus striolatus | (55) |
| BuIIIB   | VG--C--C--K--N--G--K--G--C--S--G--R--C--D--HAR--R--CC | 24 | Conus bullatus | (21) |
| CnIIIC   | ZG--C--C--E--P--N--L--C--T--W--C--R--N--A--C--R--Q--Q | 25 | Conus consors | (53) |
| BuIIIC   | IVDR--C--C--N--K--G--N--G--K--G--C--S--G--R--C--D--HAR--R--CC | 26 | Conus bullatus | (21) |

#### B. Mini peptide

| Sequence | AAs | Cone snail | Ref. |
|----------|-----|------------|------|
| KIIIA    | ----C-C---C-S-SW-CRDHS-CC | 16 | Conus kinoshitai | (20) |
| BuIIIc   | IVDR--C--C--N--K--G--N--G--K--G--C--S--G--R--C--D--HAR--R--CC | 26 | |
| Mini     | ----*C--C---C--S--R--W--R--D--H--S--R--C--C | 13 | |

#### C. Series

| Series | Sequence | AAs | Cone snail | Ref. |
|--------|----------|-----|------------|------|
| Series 1 | Mini | ----C--C--S--S--W--R--D--H--S--R--C--C--C | 13 | |
| R5A-Mini | C--C--S--S--W--R--D--H--S--R--C--C--C | 13 | |
| R5E-Mini | C--C--S--S--W--R--D--H--S--R--C--C--C | 13 | |
| Extra-Mini | C--C--S--S--W--R--D--H--S--R--C--C--C | 13 | |
| Midi | ----C--C--S--S--W--R--D--H--S--R--C--C--C | 14 | |

| Series 2 | Sequence | AAs | Cone snail | Ref. |
|----------|----------|-----|------------|------|
| Midi | ----C--C--S--S--W--R--D--H--S--R--C--C--C | 14 | |
| EAD-Midi | ----E--C--S--S--W--R--D--H--S--R--C--C--C | 16 | |
| EAK-Midi | ----E--C--S--S--W--R--D--H--S--R--C--C--C | 16 | |
| AA-Midi | ----C--C--S--S--W--R--D--H--S--R--C--C--C | 15 | |

| Series 3 | Sequence | AAs | Cone snail | Ref. |
|----------|----------|-----|------------|------|
| Midi | ----C--C--S--S--W--R--D--H--S--R--C--C--C | 14 | |
| R1-Midi | ----C--C--S--S--W--R--D--H--S--R--C--C--C | 14 | |
| R2-Midi | ----C--C--S--S--W--R--D--H--S--R--C--C--C | 14 | |
| R3-Midi | ----C--C--S--S--W--R--D--H--S--R--C--C--C | 14 | |
Miniaturized μ-Conotoxins as Selective Naᵥ Blockers

First Series of Analogues—Its short sequence makes the Mini peptide an interesting starting point for further structure-function optimization. Therefore, three series of peptides were developed based on the Mini peptide (overview in Table 1C). In a research study, Zhang et al. (35) nicely demonstrated the importance of several residues in KIIIA by means of an alanine scan. The original KIIIA peptide has a slight preference for the Naᵥ1.2 over the Naᵥ1.4 isoform (Table 2) (22). One of the analogues that was tested in the study, KIIIA(K7A), strongly influenced the discrimination between Naᵥ1.2 and Naᵥ1.4 (Table 2).

We integrated this in our design strategy, resulting in the two analogues Mini-R5A and Mini-R5E. A third peptide was based on results of Han et al. (34). They established that the adjacent Ser⁵ and Ser⁶ in KIIIA could be replaced by a PEG backbone without severely affecting the block on Naᵥ1.2 (Table 2). This prompted us to hypothesize that Ser⁴ in the Mini peptide may also be excluded. The resulting peptide was named Extra-Mini as it contained only 12 AAs. The last peptide in this series was named Midi peptide and comprised one extra Ala. It was incorporated where initially the third Cys residue was removed in KIIIA/BullIC. This was conducted to restore the appropriate spacing as we suspected spacing to be important for the correct formation of the α-helix (36) (Table 1C, Series 1).

Second Series of Analogues—Because the Midi peptide of Series 1 exhibited the best results of all tested peptides (see “Electrophysiological Characterization”), we started from this sequence in developing the second series of peptides. In EAD-Midi and EAK-Midi, a negative charge was removed in the third loop; instead, a neutralizing Ala was incorporated. This was done in accordance with results of Schroeder et al. (37), who demonstrated that removing Asp¹⁵ in SIIIA (Conus striatus) caused a 10-fold increase in Naᵥ1.2 affinity, resulting in a 70-fold neuronal selectivity of Naᵥ1.2 over Naᵥ1.4. We combined this with the addition of extra C- and N-terminal residues to examine the influence of positive or negative charges. N-terminally, an extra Glu was integrated. C-terminally, an extra Asp providing a negative charge or a Lys providing a positive charge was incorporated (Table 1C, Series 2). Finally, to further explore the effects of spatial distance in the Midi peptide, one extra Ala was integrated in the Midi sequence immediately next to the first extra Ala. This gave rise to AA-Midi (Table 1C, Series 2).

Third Series of Analogues—The Midi peptide acted once more as our starting point for the third series of peptides. This series was based on the general knowledge that basic residues are important for binding of μ-conotoxins (38, 39). Likewise, the analog SIIIA(H16R) was 137 times more selective for the neuronal Naᵥ1.2 isoform compared with Naᵥ1.4 (37). We endeavored to obtain a similar selectivity profile by replacing His¹⁰ with an Arg in the Midi peptide. Furthermore, we investigated the effect of introducing similar mutations in the first and second loops and altered Asn² and Ser⁴ individually into Arg. The resulting peptides were named R1-Midi, R2-Midi, and R3-Midi (Table 1C, Series 3).

Folding of Mini and Analogues

To investigate the folding of the Mini peptide, changes in HPLC retention time were followed and compared with the retention time of the reduced peptide (supplemental Fig. S1). When the first folding strategy was used, folding was rather slow and resembled the slow rearrangement folding of GIHIA from Conus geographus (23). HPLC profiles of aliquots quenched at 30 s, 30 min, 60 min, and 24 h displayed minor accumulation of the folded Mini peptide. Only after 1 week was a clear accumulation of folded peptide observed with minor traces of the non-folded forms. After 1 month, the HPLC profile did not differ significantly from that witnessed after 1 week, suggesting that folding reached a maximum after 1 week. The second folding strategy rather resulted in a rapid collapse pattern and reached a maximum after 30 min (supplemental Fig. S1). This is comparable with the folding of PIHIA (Conus purpurascens) and SmIIIA (Conus sternula-muscarnum) (23). To confirm folding, HPLC peaks were freeze-dried and analyzed by means of electrospray ionization MS. The corresponding molecular masses indicated that the Mini peptide was folded (monoisotopic mass, 1621.8 Da; calculated mass, 1620.8 Da). For all analogues of the Mini peptide, the second method was used as folding strategy (data not shown).

Electrophysiological Characterization

Mini Peptide—The effects of the Mini peptide were evaluated on a series of Naᵥ isoforms expressed in X. laevis oocytes. The Mini peptide reduced the peak Na⁺ current in all tested isoforms. At 20 μM, the largest block was seen on Naᵥ1.2 (63.3 ± 4.9%) followed by Naᵥ1.4 (46.6 ± 1.8%) and Naᵥ1.6 (37.9 ± 3.9%). A minor effect was noticed on Naᵥ1.5 (15.4 ± 2.7%), Naᵥ1.7 (19.9 ± 4.3%), and Naᵥ1.8 (17.3 ± 4.2%). On Naᵥ1.3, a median effect was established (36.6 ± 3.7%) (Fig. 1).

Series 1—R5E-Mini, R5A-Mini, and Extra-Mini exhibited a minor to no block on Naᵥ1.2, Naᵥ1.4, and Naᵥ1.6 at 75 nM (Fig. 2, Series 1). Only concentrations starting from 10 μM were able
the contrary displayed a large block on Nav1.2, and thus, if appropriate. Mini preferentially blocks Nav1.2 (63.3% versus 20.7%), which was as follows for other isoforms (mean ± S.E.): Na1.3, 36.6 ± 3.7%; Na1.5, 15.4 ± 2.7%; Na1.7, 19.9 ± 4.3%; and Na1.8, 17.3 ± 4.2%.

to induce a small block on these three isoforms (data not presented). The Midi peptide in contrast displayed a major block of 52.2 ± 1.2% on Na1.2 at 75 nM. Consequently, blocking characteristics of the Midi peptide were further examined, and concentration-response curves were fitted (Fig. 3A). IC50 values were 77.8 ± 5.9 nM for Na1.2, 53.4 ± 2.0 nM for Na1.4, 2373.1 ± 94.1 nM for Na1.5, and 1157.2 ± 27.4 nM for Na1.6. Na1.3 and Na1.5 could only be blocked with concentrations starting from 100 nM. When a concentration of 10 μM was used, both isoforms were blocked around 40%. As such, the corresponding IC50 values are of relative meaning, and represented concentration-response curves are only based on the available data up to 10 μM.

Series 2—Unfortunately, all three peptides of the second series (EAD-Midi, EAK-Midi, and AA-Midi) exhibited minor to no block on Na1.2 at a concentration of 75 nM (less than 5%; Fig. 2, Series 2). The block only started from concentrations in the micromolar range. The equivalent was observed for isoforms Na1.4 and Na1.6 where the block also only started at micromolar concentrations (data not presented).

Series 3—The last series of peptides comprises R1-Midi, R2-Midi, and R3-Midi. R1-Midi had an activity profile comparable with the Midi peptide. Likewise, it offered a comparable inhibition of the current of Na1.2 at 75 nM. R3-Midi presented a somewhat weaker inhibition (only 37.0 ± 5.7%). R2-Midi on the contrary displayed a large block on Na1.2, and thus, R2-Midi appeared to be the most potent blocker of all peptides tested (Fig. 2, Series 3). A concentration-response curve for R2-Midi was constructed for Na1.2, yielding an IC50 value of 34.1 ± 0.01 nM (Fig. 3B).

Comparison of the Effects of the Three Most Interesting Peptides

When comparing the effects of 75 nM Midi on different isoforms, it was observed that Midi blocked Na1.2 to a similar extent as Na1.4 (52.2 versus 51.7%, respectively) followed by Na1.6 (41.2%). The isoforms Na1.3, Na1.5, and Na1.8 were not blocked by Midi at 75 nM (Fig. 4). R1-Midi, however, made a clear distinction between Na1.2 (56.0 ± 1.9%) over Na1.4 (39.7 ± 2.6%) and Na1.6 (only 22.5 ± 2.5%). R2-Midi displayed the largest block of all three peptides on Na1.2 (70.3 ± 2.4%). Furthermore, 75 nM R2-Midi exhibited a block of 45.5 ± 0.7% on Na1.4 and 45.5 ± 1.1% on Na1.6 (Fig. 4).

When a one-way analysis of variance Bonferroni statistical analysis was performed on these results, Midi differed significantly for Na1.2 compared with the other isoforms (p < 0.05). However, the block was not significantly different for Na1.2 compared with Na1.4. The same holds true for Na1.3 against Na1.5 and Na1.8 (p > 0.05). The effects of R1-Midi differed significantly for Na1.2 set against all other isoforms (p < 0.05). For Na1.3, Na1.5, and Na1.8, no significant differences were observed. For R2-Midi, comparable degrees of block were noticed on Na1.4 and Na1.6 and on Na1.5 and Na1.8 (p > 0.05). Interestingly, the residual currents on Na1.2 displayed by R1-Midi (9.8 ± 0.5%) and R2-Midi (4.5 ± 0.7%) were somewhat larger than the residual current displayed by Midi itself (1.2 ± 1.1%).
Kinetics and Voltage Dependence of Block

To investigate the reversibility of block and determine kinetics of block of Midi, R1-Midi, and R2-Midi, washouts were conducted on Nav1.2. For all peptides, the block could be reversed, albeit often very slowly. Therefore, exact kinetics of block could not be determined. Effects on the voltage dependence of activation and steady-state inactivation were analyzed for Midi and R2-Midi on Nav1.2. No shifts were observed in the activation and steady-state inactivation curves of Midi and R2-Midi (supplemental Fig. S2).

NMR Spectroscopy

The solution structure of the Midi peptide was determined by NMR spectroscopy. The quality of the calculated structure was evaluated by means of the root mean square deviation values from the average structure (Table 3). The Midi peptide adopted a flexible structure without the typical \( \alpha \)-helix observed in \( \mu \)-conotoxins (Fig. 5A). Its N- and C-terminal regions differed greatly from the corresponding regions in KIIIA(C1A,C9A) in which the same disulfide bridge was removed as for the Midi peptide. However, some key basic residues appeared to be distributed in a manner similar to that in KIIIA(C1A,C9A) (Fig. 5B). Models of KIIIA(C1A,C9A) were generated using the solution structure deposited in the BioMagResBank (accession number 20049) by Khoo et al. (36). The solution structure of the Midi peptide was deposited in the Protein Data Bank under code 2LU6.

DISCUSSION

In current study, we demonstrate a successful strategy to design small subtype-selective compounds. A series of 11 peptides were developed, all of which established a block on Na\(_s\).s. The initial Mini peptide demonstrated activities at micromolar concentrations, and this was substantially improved by modification of the Mini peptide. The Mini peptides demonstrated activity on Na\(_1.2\), Na\(_1.3\), Na\(_1.4\), Na\(_1.5\), Na\(_1.6\), and Na\(_1.8\) at a concentration of 75 nM. When no block is seen at that concentration, this is represented by an arbitrary value of 1% for the clarity of the figure. This is the case for Midi on Na\(_1.3\), Na\(_1.5\), and Na\(_1.8\) and for R1-Midi and R2-Midi on Na\(_1.5\) and Na\(_1.8\). Other specific values are discussed under “Results.” Data are represented as the means ± S.E. (indicated by error bars); each experiment was performed at least three times (\( n \approx 3 \)).

![Figure 3](http://www.jbc.org/)

**FIGURE 3.** Concentration-response curves for the Midi peptide and R2-Midi. A, Midi was tested in different concentrations on a range of isoforms to obtain the corresponding IC\(_{50}\) values. B, R2-Midi was tested in different concentrations on Nav1.2. The asterisk indicates the IC\(_{50}\) value of R2-Midi on Nav1.2, being 34.1 nM ± 0.01. Currents were obtained as described under “Experimental Procedures.” The percentage of block was plotted against the logarithm of the tested concentrations. For all Na\(_s\) isoforms, results were fit with the Hill equation. IC\(_{50}\) values of the Midi peptide were 77.8 ± 5.9 nM for Na\(_1.2\), 53.4 ± 2.0 nM for Na\(_1.4\), 2373.1 ± 94.1 nM for Na\(_1.5\), and 115.7 ± 27.4 nM for Na\(_1.6\). IC\(_{50}\) values for Na\(_1.3\) and Na\(_1.5\) are of relative meaning as they are only blocked by concentrations starting from 100 nM.

![Figure 4](http://www.jbc.org/)

**FIGURE 4.** Overview of block by Midi, R1-Midi, and R2-Midi. The three peptides were tested on Na\(_1.2\), Na\(_1.3\), Na\(_1.4\), Na\(_1.5\), Na\(_1.6\), and Na\(_1.8\) at a concentration of 75 nM. When no block is seen at that concentration, this is represented by an arbitrary value of 1% for the clarity of the figure. This is the case for Midi on Na\(_1.3\), Na\(_1.5\), and Na\(_1.8\) and for R1-Midi and R2-Midi on Na\(_1.5\) and Na\(_1.8\). Other specific values are discussed under “Results.” Data are represented as the means ± S.E. (indicated by error bars); each experiment was performed at least three times (\( n \approx 3 \)).

![Table 3](http://www.jbc.org/)

**TABLE 3**

Structure statistics of the Midi peptide derived from NMR structural analysis

| Quantity                                      | Value          |
|-----------------------------------------------|----------------|
| Total unambiguous distance restraints          | 179            |
| Intraresidual                                 | 128            |
| Sequential (\(i-j=1\))                        | 34             |
| Medium (2 < |i-j| < 4)                                    | 10             |
| Long range (5 < |i-j| < 5)                                  | 7              |
| Dihedral angles                               | 29             |
| r.m.s.d. from the average atomic coordinates (Å) | 3.41 ± 1.67   |
| Backbone (N, C\(^*\), C\(^\ast\))             | 2.63 ± 1.31    |
| Heavy atoms                                   | 2.323 ± 0.521  |
| Deviation from idealized covalent geometry    |                |
| Bond (Å)                                      | 0.0006 ± 0.0000 |
| Angles (°)                                    | 2.882 ± 0.085  |
| Improper (°)                                  | 2.323 ± 0.521  |
| Ramachandran analysis (%)                     |                |
| Residues in most favored regions              | 49.6           |
| Residues in additional allowed regions        | 49.6           |
| Residues in generously allowed regions        | 0.8            |
| Residues in disallowed regions                | 0              |
**Miniaturized \(\mu\)-Conotoxins as Selective \(\text{Na}_v\) Blockers**

KIIIA and Midi exhibit comparable potencies with IC\(_{50}\) values on \(\text{Na}_1.2\), \(\text{Na}_1.4\), and \(\text{Na}_1.6\) around nanomolar concentrations (22). Notwithstanding the nearly complete block on \(\text{Na}_1.4\) by BuIIIC at 1 \(\mu\)M, Midi demonstrated a smaller block on \(\text{Na}_1.4\) at the same concentration (Table 2). Moreover, the block is only complete at a 10-fold higher concentration. Possibly, the bulky structure of BuIIIC (27 AAs) allows a more complete occlusion of the \(\text{Na}^+\) conduction pathway at lower concentrations. Besides a larger steric hindrance of \(\text{Na}^+\) ions for BuIIIC, additional positive charges in BuIIIC can cause a larger electrostatic repulsion than for the Midi peptide. The mutant R2-Midi in which an extra positive charge also leads to lower IC\(_{50}\) values confirms this hypothesis, which was also proposed previously (40).

Spacing is important for the activity of the Midi peptide. However, this also applies to the Extra-Mini peptide in which Ser\(^\alpha\) was additionally eliminated. Our results indicate that this distorts the formation of a bioactive scaffold. This probably hinders the appropriate binding of its key residues to the \(\text{Na}_v\) channel. Once Arg\(^\alpha\) in Mini was replaced either by an Ala resulting in Mini-R5A or by a Glu resulting in Mini-R5E, activities were also severely affected. This concurs with previous studies in which the corresponding Arg was suggested to be determinant for block of \(\text{Na}_1.2\) and \(\text{Na}_1.4\) (35, 37, 41).

For the second series of peptides, additional N- and C-terminal residues were added to the sequence of Midi. This was combined with modification of Asp\(^\alpha\) into Ala. Our results do not correspond to those of Schroeder et al. (37). They demonstrated that replacement of the corresponding Asp\(^\alpha\) in SIIIA led to a more selective \(\text{Na}_1.2\) block. For our peptides EAD-Midi and EAK-Midi, blocking activity was nonetheless seriously affected. However, our results correspond partially to those obtained for an analog of KIIIA. When Asp\(^\alpha\) in KIIIA was replaced by Ala, this caused a small reduction in block of 5% for \(\text{Na}_1.2\) and a large reduction in block of 45% for \(\text{Na}_1.4\) (calculated from data of Ref. 35). In the EAD- and EAK-Midi peptides, the simultaneous introduction of three mutations at once was probably a deleterious combination.

The final series of peptides provided us with interesting data concerning the role of basic residues in the interactions of \(\mu\)-conotoxins with \(\text{Na}_v\) channels. The importance of basic residues in the binding of the \(\mu\)-conotoxins with \(\text{Na}_v\) channels has been established previously. Residue Arg\(^3\) of GIIIA has been one of the most intensively studied residues in this respect. It was established to bind to a negative charge (Glu\(^759\)) in DII of \(\text{Na}_1.4\) (42). Likewise, interactions were demonstrated between Arg\(^9\) of GIIVA and residues Asp\(^\alpha\) and Glu\(^62\) in the P-S6 loop of DII of \(\text{Na}_1.4\) (43). Based on the potent block of R1-Midi and R2-Midi on \(\text{Na}_1.2\), \(\text{Na}_1.4\), and \(\text{Na}_1.6\), it can be stated that basic amino acids are key residues for a strong binding of the peptide to the channel (Fig. 4). Nevertheless, the most striking compound in this series is undoubtedly R2-Midi because this compound exhibits a very potent and selective block on \(\text{Na}_1.2\). Consequently, this makes R2-Midi an interesting compound for development as a therapeutic agent in \(\text{Na}_1.2\)-related diseases such as epilepsy.

As demonstrated for KIIIA (22), SIIIA (15), PIIIA (41), and certain derivatives of GIIVA (40), the block was never complete.

---

**FIGURE 5. NMR structure of the Midi peptide.** A, stereoviews of a family of 20 final structures of the Midi peptide superimposed over backbone heavy atoms (N, C\(^a\), and C\(^\alpha\)) with disulfide bonds colored gold. B, front and back views of the closest-to-average structure of the Midi peptide (top) and KIIIA(C1A,C9A) where the first disulfide bridge is removed (bottom) with side chain heavy atoms of key residues displayed and labeled. Disulfide bridges are colored gold, positively charged residues are blue, negatively charged residues are red, hydrophilic residues are green, and aromatic residues are magenta. The two views are related by a 180° rotation around the vertical axis.

concentrations. KIIIA and Mini have identical selectivity profiles, and both block Na\(_1.2\) to a larger extent than Na\(_1.4\) (Table 2) followed by Na\(_1.6\) (35, 36). This might in part be caused by the presence of a Trp residue (Trp\(^6\) in Mini and Trp\(^8\) in KIIIA) as suggested previously (22, 35).

An extra Ala residue added to the sequence of the Mini peptide to restore the spacing (in comparison with the original \(\mu\)-conotoxins) led to a peptide active in nanomolar concentrations. This may imply that the difference in biological activity of Mini (in a micromolar range) and Midi (in a nanomolar range) can be due to a difference in spacing and that at least six residues are required to set up a fully functional bioactive scaffold that can interact properly with a binding area on the Na\(_v\) channel (37). Interestingly, an \(\alpha\)-helix does not appear to be strictly necessary for the biological activity of \(\mu\)-conotoxins because this structure was not identified within the Midi peptide as defined by NMR. In KIIIA, this \(\alpha\)-helix is situated between Lys\(^5\) and His\(^12\) (36).
Miniaturized μ-Conotoxins as Selective Na⁺ Blockers

for any of the peptides that could be tested at their maximum concentrations (e.g. Midi, R1-Midi, and R2-Midi). Charge-neutralizing substitutions at three positions in PIIIA also caused a residual current. It was suggested that its basic residues interact with channel residues close to the Na⁺ conduction pathway. Thereby, the pore of the channel is blocked electrostatically or sterically (41). However, this toxin-channel interaction could allow some Na⁺ ions or even tetrodotoxin to sneak by, causing a residual current (12, 16, 24, 40). A small residual current was similarly observed for derivatives of GIIIA at one single position (Arg⁴¹). Nonetheless, following this reasoning, R1-Midi and R2-Midi should cause more electrostatic repulsion compared with Midi due to the addition of a positive Arg. Their residual currents should be smaller as opposed to those of the Midi peptide. However, this is not the case. Possibly, there are supplementary, non-electrostatic components that contribute to the mechanism of block observed for R1-Midi and R2-Midi. Recently, it was proven by molecular dynamic simulations for PIIIA that differences in binding affinity on Na₄,1.4 can be due to a slightly different location of binding in the pore region. One of its structural isomers was simulated to bind to a region located deeper in the pore, correlating to a higher binding affinity on Na₄,1.4 (44). Consequently, small differences in binding affinities reveal that our μ-conotoxin derivatives bind at slightly different regions, although all located in the pore and therefore leading to block of Na⁺ conduction.

Interestingly, our NMR data indicate that Midi adapts a rather flexible structure devoid of an α-helix. All 3JHα-Hα coupling constants extracted from double quantum-filtered COSY spectra (measured at 5 °C; data not displayed) are between 6 and 8 Hz, indicative of a very flexible structure. Despite the lack of an α-helix, the Midi peptide blocks Na,s at nanomolar concentrations. This is in accord with recent studies of an isomer of PIIIA that also had a flexible conformation but remained active on Na₄,1.4 (44). Apparently, an α-helix is not strictly essential to acquire a fully active peptide. Possibly, some of the basic residues incorporated in the Midi peptide are distributed in a manner close to the arrangement in KIIIA(C1A,C9A) (Fig. 5B), leading to a similar activity profile. Further evidence is presented by Chen and Chung (45), who suggest that PIIIA may block the Na₄ with various binding modes. Different basic residues can thereby all protrude into the selectivity filter and block the pore, whereas other residues can make electrostatic contacts at the outer vestibule of the channel. Because the basic residues of Midi are also symmetrically distributed, this allows the peptide to form multiple binding modes with the Na₄ channel. It will be interesting to generate molecular dynamics simulations for Midi as well.

For a peptide to be eligible for development as a therapeutic compound, it is essential that it remains stable in vivo. To improve stability, cyclic peptides or lactam-stabilized peptides can be formed (46). This can for instance be achieved by means of native chemical ligation (for a review, see Ref. 47). Regardless, whether these modifications do not influence the activities of the peptides and whether they still exhibit the same potencies as the original peptides need be determined.

With our results, we prove that it is possible to design very small peptides based on known pharmacophores of μ-conotoxins without losing their potency and therapeutically important selectivity. We confirm that removal of one disulfide bridge does not affect their activity. By defining the NMR structure of the Midi peptide, we deliver evidence that the α-helical structure that has traditionally been considered as responsible for the biological activity of μ-conotoxins is not strictly necessary. Finally, we demonstrate that it is possible to obtain more selective peptides by thoughtfully mutating particular amino acids in the sequence of μ-conotoxins. Therefore, our miniaturized compounds are an ideal starting platform in the pursuit of novel therapeutics that can be used to treat Na₄-related diseases such as epilepsy (48) and pain (34, 35).

Acknowledgments—We thank A. L. Goldin (University of California, Irvine, CA) for sharing rNa,1.2, rNa,1.3, and mNa,1.6; G. Mandel (Stony Brook University, Stony Brook, NY) for sharing rNa,1.4; R. G. Kallen (University of Pennsylvania, Philadelphia, PA) for sharing hNa,1.5; P. Dietrich (Roche Applied Science) for sharing rNa,1.7; J. N. Wood (University College, London, UK) for sharing rNa,1.8; S. H. Heinemann (Friedrich-Schiller-Universität, Jena, Germany) for sharing the rβ1 subunit; and S. C. Cannon (University of Texas, Dallas, TX) for sharing the hβ1 subunit. We are also grateful to Elia Diego-Garcia, Bert Billen, Annelies Van Der Haegen, and Sarah Dehaye for helpful discussions and/or technical assistance and to Nick Van Nuffelen for carefully proofreading this manuscript.

REFERENCES

1. Escayg, A., and Goldin, A. L. (2010) Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia 51, 1650–1658
2. Jurkat-Rott, K., Holzherr, B., Fauler, M., and Lehmann-Horn, F. (2010) Sodium channelopathies of skeletal muscle result from gain or loss of function. Pflugers Arch. 460, 239–248
3. Campuzano, O., Beltrán-Alvarez, P., Iglesias, A., Scornik, F., Pérez, G., and Brugada, R. (2010) Genetics and cardiac channelopathies. Genet. Med. 12, 260–267
4. Mantegazza, M., Curia, G., Biagini, G., Ragsdale, D. S., and Avoli, M. (2010) Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 9, 413–424
5. Shon, K. J., Grilley, M. M., Marsh, M., Yoshikami, D., Hall, A. R., Kurz, B., Gray, W. R., Imperial, J. S., Hillyard, D. R., and Olivera, B. M. (1995) Purification, characterization, synthesis, and cloning of the lockjaw peptide from Conus purpurascens venom. Biochemistry 34, 4913–4918
6. Buczek, O., Wei, D., Babon, J. J., Yang, X., Fiedler, B., Chen, P., Yoshikami, D., Olivera, B. M., Bulaj, G., and Norton, R. S. (2007) Structure and sodium channel activity of an excitatory I1-superfamily conotoxin. Biochemistry 46, 9929–9940
7. McIntosh, J. M., Hasson, A., Spira, M. E., Gray, W. R., Li, W., Marsh, M., Hillyard, D. R., and Olivera, B. M. (1995) A new family of conotoxins that blocks voltage-gated sodium channels. J. Biol. Chem. 270, 16796–16802
8. Spence, L., Gillessen, D., Gregson, R. P., and Quinn, R. J. (1977) Characterization of the neurotoxic constituents of Conus geographus (L) venom. Life Sci. 21, 1759–1769
9. Tesfau, H., and Olivera, B. M. (2004) Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol. Rev. 84, 41–68
10. Ekberg, J., Craik, D. J., and Adams, D. J. (2008) Conotoxin modulation of voltage-gated sodium channels. Int. J. Biochem. Cell Biol. 40, 2363–2368
11. Lewis, R. I., Dutertre, S., Vetter, I., and Christie, M. J. (2012) Conus venom peptide pharmacology. Pharmacol. Rev. 64, 259–298
12. Zhang, M. M., Gruszczynski, P., Walewska, A., Bulaj, G., Olivera, B. M., and Yoshikami, D. (2010) Cooccupancy of the outer vestibule of voltage-gated sodium channels by micro-conotoxin KIIIA and saxitoxin or tetrodotoxin. J. Neurophysiol. 104, 88–97
13. Stephan, M. M., Potts, J. F., and Agnew, W. S. (1994) The microl skeletal...
Miniaturized \( \mu \)-Conotoxins as Selective Na\(_\nu\) Blockers

channels in amphibian sympathetic and sensory neurons. *Biochemistry* 41, 15388–15393

53. Zhang, M. M., Fiedler, B., Green, B. R., Catlin, P., Watkins, M., Garrett, J. E., Smith, B. J., Yoshikami, D., Olivera, B. M., and Bulaj, G. (2006) Structural and functional diversities among \( \mu \)-conotoxins targeting TTX-resistant sodium channels. *Biochemistry* 45, 3723–3732

54. Favreau, P., Benoit, E., Hocking, H. G., Carlier, L., D’Hoedt, D., Leipold, E., Markgraf, R., Schlumberger, S., Córdova, M. A., Gaertner, H., Paolini-Bertrand, M., Hartley, O., Tytgat, J., Heinemann, S. H., Bertrand, D., Boeles, R., Stöcklin, R., and Molgö, J. (2012) Pharmacological characterization of a novel \( \mu \)-conopeptide, CnIIIC, indicates potent and preferential inhibition of sodium channel subtypes (Na\(_\nu\)1.2/1.4) and reveals unusual activity on neuronal nicotinic acetylcholine receptors. *Br. J. Pharmacol.* 166, 1654–1668

55. Walewska, A., Skalicky, J. J., Davis, D. R., Zhang, M. M., Lopez-Vera, E., Watkins, M., Han, T. S., Yoshikami, D., Olivera, B. M., and Bulaj, G. (2008) NMR-based mapping of disulfide bridges in cysteine-rich peptides: application to the \( \mu \)-conotoxin SxIIIA. *J. Am. Chem. Soc.* 130, 14280–14286
Protein Structure and Folding:
Design of Bioactive Peptides from Naturally Occurring μ-Conotoxin Structures

Marijke Stevens, Steve Peigneur, Natalia Dyubankova, Eveline Lescrinier, Piet Herdewijn and Jan Tytgat
J. Biol. Chem. 2012, 287:31382-31392.
doi: 10.1074/jbc.M112.375733 originally published online July 6, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M112.375733

Find articles, minireviews, Reflections and Classics on similar topics on the JBC Affinity Sites.

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2012/07/06/M112.375733.DC1.html

This article cites 54 references, 14 of which can be accessed free at http://www.jbc.org/content/287/37/31382.full.html#ref-list-1